Skip to main content
European Radiology Experimental

Table 2 Cancer therapy–related cardiac dysfunction of the entire study group and subgroups

From: Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy

Variable

Entire study group (n = 24)

Dual anti-HER2 group (n = 16)

Trastuzumab group (n = 8)

LVEF decline > 10% to less than 55%

2 (8.33)

2 (8.33)

0 (0.0)

GLS change > 15%

6 (25.00)

5 (20.83)

1 (4.17)

Symptomatic heart failure

1 (4.17)

1 (4.17)

0 (0.0)

  1. Data in parentheses are percentages out of the entire group. GLS Global longitudinal strain; HER2 Human epidermal growth factor receptor 2, LVEF Left ventricular ejection fraction
Back to article page